Delcath Systems (NASDAQ:DCTH) Issues Earnings Results

Delcath Systems (NASDAQ:DCTH) released its quarterly earnings data on Thursday. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16, FiscalAI reports. Delcath Systems had a net margin of 0.56% and a return on equity of 0.47%. The firm had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million.

Here are the key takeaways from Delcath Systems’ conference call:

• HEPZATO revenue and guidance increased: Second-quarter HEPZATO KIT revenue reached $27.1 million, up 21% year over year, while volume rose 30% despite the impact of 340B pricing. Delcath raised full-year 2026 revenue guidance to $104 million-$108 million and expects positive adjusted EBITDA.
• Commercial footprint continued to expand: The company activated two treatment centers in the quarter, reaching 31, and remains confident it can reach approximately 37 centers by year-end. New patient starts averaged about 0.5 per site per month, with leading NCI- and NCCN-affiliated institutions making up a substantial portion of the network.
• Expansion into additional cancers is progressing but remains early: Phase II studies in third-line liver-dominant colorectal cancer and HER2-negative metastatic breast cancer are adding sites and improving enrollment, while an interim colorectal readout is expected in late 2027. Management acknowledged that enrollment has been slower than initially expected because of the complexity of coordinating oncology and interventional radiology teams.
• Profitability was supported by strong gross margins, but investment and pricing pressures remain: Second-quarter gross margin improved to 90%, although full-year guidance is 86%-89% due partly to anticipated manufacturing costs. Research and development and selling, general and administrative expenses increased year over year, while adjusted EBITDA declined to $7.6 million from $9.8 million.

Delcath Systems Price Performance

NASDAQ DCTH traded down $0.36 on Friday, reaching $15.11. The stock had a trading volume of 1,212,338 shares, compared to its average volume of 498,787. The company has a market cap of $521.60 million, a P/E ratio of 1,512.51 and a beta of 0.52. The firm has a fifty day moving average of $12.35 and a two-hundred day moving average of $10.87. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $16.38.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DCTH. Weiss Ratings upgraded shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. BTIG Research upped their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday. Zacks Research raised shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently modified their holdings of DCTH. Intech Investment Management LLC increased its holdings in shares of Delcath Systems by 13.1% during the fourth quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock worth $178,000 after purchasing an additional 2,035 shares during the period. PharVision Advisers LLC bought a new stake in shares of Delcath Systems in the third quarter valued at approximately $162,000. Creative Planning bought a new stake in shares of Delcath Systems in the third quarter valued at approximately $168,000. Two Sigma Investments LP bought a new stake in shares of Delcath Systems in the third quarter valued at approximately $194,000. Finally, Franklin Resources Inc. acquired a new stake in Delcath Systems during the third quarter worth approximately $206,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.